Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma announces Late-Breaking Phase 2 Data Showing Potential of ILUMYA™

Posted On: 2019-06-14 13:38:10

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYATM (tildrakizumab-asmn) in patients with active psoriatic arthritis that was presented in a late-breaking oral presentation at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain (abstract #LB-0002).1 The interim analysis revealed that over 71 percent of patients treated with ILUMYA™ experienced a 20 percent improvement in joint and skin symptoms (ACR20), meeting the primary endpoint of the study. The interim results showed ILUMYA™ was well tolerated with a low rate of serious treatment-emergent adverse events.

ILUMYA™ is approved in the U.S. for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and is being investigated for psoriatic arthritis. Psoriatic arthritis, which affects up to 42 percent of people with plaque psoriasis, is an inflammatory condition that impacts both the joints and skin. It is painful, causes fatigue, and can lead to swelling and stiffness of the joints that may reduce range of motion. If left untreated, this chronic condition can lead to permanent joint damage.2,3,4

"As a researcher and clinician, it's encouraging to see these improvements in pain, joint swelling and skin plaques. Our interim findings showed that about half of the patients treated with 100 mg or 200 mg of tildrakizumab saw a 50 percent improvement in psoriatic arthritis symptoms and about a quarter saw a 70 percent improvement within 24 weeks," said study investigator Philip J. Mease, MD, MACR, director of rheumatology research at the Swedish Medical Center/Providence St Joseph Health and clinical professor at the University of Washington School of Medicine, Seattle, WA. "These data insights are promising for patients who continue to struggle with the impact psoriatic arthritis has on their daily lives."

The Phase 2 study interim results showed that across all patients receiving ILUMYA™, 75.3 percent experienced a 20 percent improvement in symptoms of psoriatic arthritis (ACR20) at week 24 compared to 50.6 percent of patients on placebo. The findings were similar in patients receiving 100mg or 200 mg of ILUMYA™ on a quarterly dosing schedule. For some patients on 100 mg ILUMYA™, results were seen as early as 8 weeks. Furthermore, an average of 47.1 percent of all patients receiving ILUMYA™ achieved an ACR50 response with some results seen as early as 12 weeks, compared to 24.1 percent of patients on placebo.

The interim results also showed ILUMYA™ was well tolerated with a low and comparable rate of adverse events to placebo. Serious treatment-emergent adverse events occurred in 2.2 percent of patients treated with ILUMYA™ and 2.5 percent in those on placebo, with no patients discontinuing treatment due to these events. The most common adverse events through week 24 included common cold (nasopharyngitis), upper respiratory tract infection, and headache. There were no reports of candidiasis, inflammatory bowel disease, major adverse cardiac events, malignancy, or deaths.

"We are committed to the continued clinical development of ILUMYA™ and are pleased with the interim results in our first study for psoriatic arthritis," said Kyle Ferguson, Business Unit Head, Vice President Sales & Marketing, Sun Pharma. "To help us determine the potential of ILUMYA™ across psoriatic disease, we are now exploring a possible Phase 3 trial for psoriatic arthritis with regulatory authorities."

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.390.1 as compared to the previous close of Rs. 391.65. The total number of shares traded during the day was 193543 in over 2692 trades.

The stock hit an intraday high of Rs. 393.6 and intraday low of 385.7. The net turnover during the day was Rs. 75306141.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Granules India Limited receives US FDA approval for Fexofenadine Hydrochloride Tablets

Onmobile enters into partnership with Bharti Airtel to power games on Thanks App

Oberoi Realty Ltd consolidated Q2 net profit slips to Rs.138.07 crore

Subscriber base of RIL's Digital Services Business at 355.2 million as of Sep 30, 2019

Sasken Technologies Ltd reports consolidated EPS of Rs. 13.34 in Q2 FY 2019-20

RIL's Media Business reports robust growth in subscription income

HDFC Bank Limited announces Q2 FY2019-20 results

RIL's revenue from Organized Retail Business up 27% YoY to Rs. 41202 crore in Q2

DCB Bank announces Second Quarter FY 2020 Results

RIL's revenue from Oil and Gas Business declines to Rs. 790 crore in Q2

Cementing a Green Future

RIL's Petrochemicals Business Q2 revenue down 11.9% YoY

Siyaram Silk Mills Ltd Board declares Interim Dividend, onetime special dividend

HDB Financial Services Ltd posts net profit of Rs. 213 crore in Q2

HDFC Securities Limited Q2 PAT at Rs. 91 crore

ICRA reaffirms long term rating of Shalby Limited

Brickwork Ratings reaffirms ratings of Oriental Bank of Commerce

Brickwork Ratings updates on credit ratings of Aarvee Denims & Exports Ltd

ICRA retains credit rating of Z F Steering Gear India Ltd

Shiva Cement Ltd Q2 loss at Rs. 6.22 crore

Bhansali Engineering Polymers Ltd Q2 consolidated net profit at Rs. 20.36 crores

Dalmia Bharat Ltd posts consolidated PAT of Rs. 36 crore in Q2

Siyaram Silk Mills Ltd consolidated Q2 net profit climbs to Rs. 29.31 crore

Avanti Feeds Ltd Q2 consolidated PAT rises to Rs. 118.69 crores

DCB Bank Limited posts net profit of Rs. 91.41 crores in Q2 FY 2019-20

LIC Housing Finance Ltd Q2 consolidated PAT higher at Rs. 768.05 crores

HDFC Bank Ltd reports consolidated Q2 PAT of Rs. 6638.03 crores

Aro Granite Industries Ltd posts slump in Q2 net profit

Jasch Industries Ltd Q2 loss at Rs. 0.60 crore

Chembond Chemicals Ltd consolidated Q2 net profit slides to Rs. 1.52 crore

Shree Cement Ltd consolidated Q2 net profit at Rs. 310.62 crores

Smruthi Organics Ltd Q2 PAT at Rs. 1.89 crore

Menon Bearings Ltd Q2 PAT falls to Rs. 2.93 crore

Pioneer Distilleries Ltd Q2 loss at Rs. 19.91 crore

VTM Ltd reports net profit of Rs. 4.33 crore in Q2 FY 2019-20

National Plastic Technologies Ltd Q2 PAT climbs to Rs. 0.59 crore

RMC Switchgears Ltd is participating in ACETECH - Bengaluru 2019

3P Land Holdings Ltd posts net profit of Rs. 0.22 crore in Q2

RIL's GRM for Q2 stood at $ 9.4/bbl

Mr. Abhishek Sinha appointed as COO & Whole-Time Director of L&T Technology Services Limited

RIL consolidated Q2 PAT at Rs. 11262 crore

L&T Finance Holdings Ltd announces Q2 FY 2019-20 results

L&T Technology Services continues double-digit revenue growth in Q2FY20

Maruti Suzuki India Ltd announces introduction of Regulatory Compliant EECO

ICICI Lombard General Insurance Company Limited announces Q2 FY 2019-20 results

CARE updates on ratings of Indiabulls Housing Finance Ltd

Ambuja Cements Ltd announces Q3 CY2019 results

Digital & Consumer Electronics Brand - Xmate disrupts the Indian market by launching an extensive product portfolio

Brickwork Ratings reaffirms ratings of Punjab National Bank

L&T Technology Services Ltd Board approves Dividend of Rs. 7.50 for 2019-20







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019